SCHEMBL4784822

SCHEMBL4784822

O=c1cc(O)nc(-c2c(Cl)cccc2Cl)n1Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAPK1 P28482 1/20 0.43
ATM Q13315 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
EGLN3 Q9H6Z9 1/20 0.42
HPGD P15428 2/20 0.42
P2RX7 Q99572 1/20 0.40
BCL2 P10415 1/20 0.40
MCL1 Q07820 1/20 0.40
GPR35 Q9HC97 1/20 0.40
CCR2 P41597 2/20 0.40
APLNR P35414 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4741826 0.92 CCR2 (0.43) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL4739137 0.88 ALDH1A1 (0.52) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL4740165 0.86 KDM4E (0.48) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL4739981 0.85 EGLN3 (0.56) MEN1KMT2ASMN1; SMN2EGLN3
SCHEMBL4737051 0.83 BCL2 (0.55) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL4738470 0.82 LMNA (0.51) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL4737518 0.81 EGLN3 (0.51) MEN1KMT2AALDH1A1MAPK1EGLN3
SCHEMBL4739173 0.79 ALDH1A1 (0.48) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL3521617 0.79 ALDH1A1 (0.51) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL4737864 0.78 CFTR (0.53) MEN1KMT2AALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 MEN1 2935/4885KMT2A 734/4885ALDH1A1 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.